BioMarin Pharmaceutical valuation

BMRN · NASDAQ · USD

Compare BioMarin Pharmaceutical
$58.15Change from previous close: +1.60%Absolute change: +$0.92

Close · November 16, 2026

Valuation

The P/E ratio is 146.8. The average price target of 27 analysts is $90.78.

Data as of November 15, 2026

BioMarin Pharmaceutical compared with similar companies

BioMarin Pharmaceutical's P/E (trailing 12 months): 146.8, +168% against the median of a group of 7 similar companies (54.8).

BioMarin Pharmaceutical's metrics compared with similar companies
MetricBioMarin PharmaceuticalMedian25th–75th percentileBand
P/E (trailing 12 months)146.854.822.9 – 69.1High
Forward P/E9.0515.49.36 – 25.0Low
EV/EBITDA17.017.013.8 – 40.7Middle
Price/book1.7710.16.26 – 19.0Low
Price/sales3.038.806.44 – 13.7Low
Gross margin53.2%91.1%59.7% – 93.1%Low
Operating margin16.3%16.3%-12.6% – 29.2%Middle
Net margin-0.5%4.4%-12.9% – 21.9%Middle
ROE-0.3%8.3%-9.7% – 38.5%Middle
Debt/equity0.670.130.06 – 0.67High

Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.

TickerLandia analysisHow it is calculated

Companies in the group: same industry, similar size

BioMarin Pharmaceutical: valuation over time

On the latest fiscal year's earnings (2025), BioMarin Pharmaceutical's P/E today is 32.3, in line with the median of its last 5 fiscal years (33.0; between 19.5 and 138.0 from 2020 to 2025). Relative to earnings, it costs about the same as in the past.

BioMarin Pharmaceutical P/E and dividend yield at each fiscal year end
Fiscal yearPrice at year endEarnings per shareP/E
2025$59.43$1.8033.0
2024$65.73$2.2129.7
2023$96.42$0.87110.8
2022$103.49$0.75138.0
2021$88.35-$0.35—
2020$87.69$4.5019.5
2019$84.55-$0.13—
2018$85.15-$0.44—
2017$89.17-$0.67—
2016$82.84-$3.81—

TickerLandia calculation: closing price on the last trading day of the fiscal year divided by diluted earnings per share from the annual report (positive earnings only). Prices adjusted for splits. Today's P/E is today's price divided by the latest fiscal year's earnings per share, so it compares with the years above.

TickerLandia analysisHow it is calculated

Other metrics

Valuation multiples

Market cap
$11.09B
Enterprise value
$14.54B
PEG
0.52
EV/revenue
3.98

Profitability and growth

ROA
3.9%
ROIC
3.6%
Revenue growth (year over year)
32.0%
Earnings growth (year over year)
-81.3%

Financial health

Total cash
$736.01M
Total debt
$4.19B
Current ratio
2.44
Quick ratio
1.13
Altman Z-Score
2.00
Piotroski F-Score
3.00

Dividends

Dividend yield
0.0%
Payout ratio
0.0%

Analysts and estimates

Average price target
$90.78
Median price target
$89.00
High price target
$120.00
Low price target
$60.00
Analysts with a price target
27
Consensus
Buy
Forward EPS
$6.32
EPS estimate, current year
$3.03

Shares and trading

Beta
0.23
Average volume
2.2M
Shares outstanding
193.69M
Float
192.75M
Institutional ownership
104.4%
Insider ownership
1.1%
Short interest (% of float)
7.3%
Short ratio (days)
5.73